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Abstract
Accumulation of fibrillar amyloid -protein (A) in blood vessels of the brain, a
condition known as cerebral amyloid angiopathy (CAA), is a common pathology of
the elderly, a prominent comorbidity of Alzheimer’s disease and driver of vascular
cognitive impairment and dementia (VCID). Although several transgenic mouse
lines have been generated that develop varying levels of CAA, consistent models
of associated cerebral microhemorrhage and vasculopathy observed clinically
have

been

lacking.

Reliable

preclinical

animal

models

of

CAA

and

microhemorrhage are needed to investigate the molecular pathogenesis of this
condition. Here, we describe the generation and characterization of a novel
transgenic rat (rTg-DI) that produces low levels of human familial CAA Dutch/Iowa
E22Q/D23N mutant A in brain and faithfully recapitulates many of the pathological
aspects of human small vessel CAA. rTg-DI rats exhibit early-onset and
progressive accumulation of cerebral microvascular fibrillar amyloid accompanied
by early-onset and sustained behavioral deficits. Comparable to CAA in humans,
the cerebral microvascular amyloid in rTg-DI rats causes capillary structural
alterations, promotes prominent perivascular neuroinflammation and produces
consistent, robust microhemorrhages and small vessel occlusions that are readily
detected by magnetic resonance imaging. The rTg-DI rats provide a new model to
investigate the pathogenesis of small vessel CAA and microhemorrhages, to
develop effective biomarkers for this condition and to test therapeutic
interventions.

Introduction
Cerebral amyloid angiopathy (CAA) is a common cerebral small vessel disease
that involves the accumulation of amyloid -protein (A) primarily in small- and mediumsized arteries and arterioles of the meninges and cerebral cortex as well as along the
capillaries of the cerebral microvasculature

1-6.

CAA has been shown to be present, in

varying degrees, in nearly 80% of elderly individuals

7,8.

With the involvement of A, it is

not surprising that CAA is a very common vascular comorbidity in patients with
Alzheimer’s disease (AD) 3,7-9. Even when controlling for confounders including AD, CAA
is a significant contributor to vascular-mediated cognitive impairment and dementia
(VCID) and is independently associated with worse cognition and dementia

7,8,10-13.

In

addition to the sporadic cases of CAA and the prominent CAA that is observed in AD,
several monogenic, familial forms of CAA exist that result from mutations that reside
within the A peptide sequence of APP gene including the Dutch E22Q and Iowa D23N
variants 12-14.
CAA can present as two prominent forms known as CAA type-1 and CAA type-2
6.

In CAA-type 2 the amyloid deposition is largely restricted within the vessel wall of the

meningeal and cortical arterioles and generally does not promote perivascular
neuroinflammation

5,6,15.

In contrast, CAA type-1 involves amyloid deposition along

transitional cerebral microvessels and capillaries and is present in nearly half of AD cases
5,6.

In contrast to larger vessel CAA type-2 where the amyloid is largely confined within

the vessel wall, CAA type-1 results in penetrance of the fibrillar amyloid deposits into the
surrounding brain parenchyma – so called “dyshorric amyloid” – a feature which promotes
a strong perivascular neuroinflammatory response

5,6,16,17.

In particular, cerebral

microvascular amyloid deposition is often correlated with worse cognition and dementia
in individuals afflicted with AD and sporadic/familial CAA disorders 18-22.
Transgenic mice, which robustly over-express human APP in brain and develop
cerebral A deposits, have been a significant advancement for the study of the
pathogenic effects of brain A accumulation in vivo. Several well-established transgenic
mouse lines have been developed that over-produce human A peptides in brain that
develop age-dependent accumulation of parenchymal A deposits with varying degrees
of CAA and associated vasculopathies

23-26.

Specifically, transgenic mouse lines were

developed that express human APP in brain harboring one or more of the familial CAA
mutations

27,28.

Importantly, these familial CAA transgenic mouse lines revealed the

specific role of CAA in neuroinflammation and VCID

29-32.

However, as with all mouse

models, CAA transgenic mice possess some significant limitations to more fully
recapitulate and study the equivalent human condition. In particular, consistent and robust
microbleeds have been elusive in most CAA mouse models. Therefore, more appropriate
animal models of small vessel CAA are necessary to progress our understanding of the
pathogenesis, its contribution to structural changes in the brain and VCID.
Here we describe our efforts to generate and characterize a new transgenic rat
model (rTg-DI) for small vessel CAA. We demonstrate that rTg-DI rats exhibit early-onset
and progressive accumulation of cerebral microvascular fibrillar amyloid accompanied by
behavioral deficits. Fibrils seeded from the vascular amyloid isolated from rTg-DI rats
exhibit intense bands in Fourier transform infrared (FTIR) spectra characteristic of
antiparallel -sheet similar to that previously observed for human cerebral vascular
amyloid

33.

Moreover, in rTg-DI rats the cerebral microvascular A deposits cause

capillary structural changes, promote prominent perivascular glial activation and produce
consistent, robust microhemorrhages with small vessel occlusions that are readily
detected by magnetic resonance imaging.

Materials and Methods
Generation of Transgenic Rats All work with animals followed National Institutes of
Health guidelines and was approved by the University of Rhode Island, Yale University
and Stony Brook University Institutional Animal Care and Use Committees. A pcDNA3
vector containing 2.1 kb of human APP (isoform 770) cDNA was used to introduce the
mutations Swedish K670N/M671L, Dutch E693Q, and Iowa D694N using the
QuikChange kit (Stratagene, La Jolla, CA). The APP770-SwDI cDNA was amplified by
PCR using primers containing the NheI 5-linker and SacII 3-linker. The PCR product was
digested and subcloned between exons II and IV of a Thy1.2 expression cassette using
NheI and SacII restriction sites. The completed construct was entirely sequenced to
confirm its integrity. The 9-kb transgene was liberated by NotI/PvuI digestion, purified,
and microinjected into pronuclei of Sprague-Dawley single cell embryos. Founder rats
were identified by Southern blot analysis of tail DNA. Transgenic offspring were
determined by PCR analysis of tail DNA using the following primers specific for human
APP:

5’-CCTGATTGATACCAAGGAAGGCATCCTG-3’

GTCATCATCGGCTTCTTCTTCTTCCACC-3’

(generating

a

and
500-bp

product).

5’All

subsequent analyses were performed with heterozygous transgenic rats.
Immunoblot Quantitation of APP. Rat forebrain tissues were homogenized in 10
volumes of 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 1% SDS, 0.5% Nonidet P40, 5 mM EDTA, and proteinase inhibitor mixture (Roche Applied Science, Indianapolis,
IN). The tissue homogenates were clarified by centrifugation at 14,000 x g for 10 min.
Protein concentrations of the resulting supernatants were determined using the BCA
protein assay Kit (Fisher Scientific, Houston, TX). The levels of APP in the forebrain

tissue homogenates were determined by performing quantitative immunoblotting as
described

27.

Samples were probed either with monoclonal antibody P2-1, which is

specific for human APP 34, or with monoclonal antibody 22C11 (Chemicon International,
Inc., Temecula, CA), which detects both rat and human APP. Bands corresponding to
APP were measured using a LICOR imaging system (Lincoln, NE).

Quantitation of A Peptides Soluble pools of Aβ40 and Aβ42 were determined by
performing specific ELISAs on carbonate extracted rat forebrain tissue and subsequently
the insoluble Aβ40 and Aβ42 levels were determined by ELISA of guanidine lysates of
the insoluble pellets resulting from the carbonate extracted rat brain tissue as described
35,36.

In the sandwich ELISAs Aβ40 and Aβ42 were captured using their respective

carboxyl-terminal specific antibodies mAb2G3 and mAb21F12 and biotinylated m3D6,
specific for human Aβ, was used for detection

35.

Cerebral microvessels were isolated

from rat forebrains as described 27,37. The levels of cerebral microvascular A40 and A42
levels were measured in guanidine lysates of the brain microvessels isolated from rTg-DI
rats. Each rat brain or microvessel lysate was measured in triplicate and compared to
linear standard curves generated with known concentrations of human Aβ using a
Spectramax M2 plate reader (Molecular Devices, Sunnyvale, CA).

Isolation of cerebral capillary amyloid seeds. Brain capillaries were isolated from the
cortices of twelve months old rTg-DI rats as described

27,37.

The isolated microvessels

were analyzed microscopically by staining with thioflavin S and immunolabeling with an
antibody to collagen IV to confirm the isolation of amyloid-containing microvessels. The

remaining microvessels were treated with 3 mg/ml collagenase at 37 oC overnight. The
collagenase treated samples were centrifuged at 16,000 x g for 5 min and the resulting
pellet was washed twice with TBS. The amyloid pellet was resuspended in TBS and again
analyzed microscopically by staining with thioflavin S and immunolabeling with an
antibody to collagen IV to confirm the isolation of vascular amyloid deposits and the
absence of microvessels.

Seeding of fibrils from vascular amyloid. For the preparation of fibrils from isolated
vascular amyloid, isolated vascular amyloid was sonicated for using a Fisher Scientific tip
sonicator at 30% power in four 10 sec bursts. Monomeric (synthetic) A40-WT peptide
was added to the seeds in 3 steps at 1 h intervals. The A40-WT peptide was synthesized
using N-t-Boc chemistry on an ABI 430A solid-phase peptide synthesizer (ERI Amyloid
Laboratory, Oxford, CT) and purified by high performance liquid chromatography (HPLC).
Based on analytical reverse phase HPLC, the peptide purity was greater than 98%. The
mass of the purified peptide was measured using matrix-assisted laser desorption or
electrospray ionization mass spectrometry and was consistent with the calculated mass
for the peptide. The peptides were isotopically labeled with 1-13C at Leu17, Ala21, Gly33
and Gly37 for FTIR measurements. Purified, lyophilized A peptides were aliquoted in
hexafluoroisopropanol and freeze-dried for at least 4 days with a vacuum of 25 mTorr.
For preparing monomeric A, the peptide was dissolved in 50 mM NaOH at a
concentration of 2.2 mM, then diluted in 10 mM phosphate buffer (pH 7.4) at low
temperature (4 °C). The Aβ solutions were then filtered with a 0.2-micron cellulose acetate

filter to remove insoluble aggregates. The Aβ concentration was determined by the
absorption at 270 nm using a molar extinction coefficient of ε=1405 cm-1·M-1.

Fluorescence spectroscopy. Thioflavin T fluorescence measurements were performed
on a SpectraMax M2 spectrofluorimeter plate reader. The Aβ peptide concentration was
100 M and the thioflavin T concentration was 50 M. Thioflavin T fluorescence was
monitored every 15 sec with excitation, emission and automatic cutoff wavelengths of
446, 490 and 475 nm, respectively.

FTIR spectroscopy. FTIR spectra were obtained on a Bruker Vertex 70 spectrometer
using a germanium attenuated total reflection (ATR) plate with a spectral resolution of 4
cm-1. Samples were prepared by drying a 50-100 l of peptide solution on the plate
surface.

Tissue Preparation. Rats were euthanized at designated time points and perfused with
cold-PBS, forebrains were removed and dissected through the mid-sagittal plane. One
hemisphere was either immersion-fixed with 70% ethanol overnight and subjected to
increasing sequential dehydration in ethanol, followed by xylene treatment and
embedding in paraffin. Alternatively, brains were fixed with 4% paraformaldehyde
overnight at 4oC and subjected to increasing concentrations (10, 20, 30%) of sucrose in
PBS, then embedded in OCT compound (Sakura Finetek Inc., Torrance, CA) and snapfrozen in dry ice. Sagittal sections were cut at 10 µm thickness using a Leica RM2135
microtome (Leica Microsystems Inc., Bannockburn, IL), placed in a flotation water bath at

40°C, and then mounted on Colorfrost/Plus slides (Fisher Scientific, Houston, TX). In
some cases, coronal sections were cut at 20 m thickness from frozen brains using a
Leica CM1900 cryostat (Leica Microsystems Inc.), stored in PBS with 0.02% sodium
azide at 4oC.

Immunohistochemical Analysis Antigen retrieval was performed by treating the tissue
sections with proteinase K (0.2 mg/ml) for 10 min at 22 °C. Primary antibodies were
detected with Alexa Fluor 594-conjugated donkey anti-rabbit or Alexa Fluor 488conjugated goat anti-mouse secondary antibodies (1:1000). Staining for fibrillar amyloid
was performed either using Amylo-Glo as described by the manufacturer (Biosensis Inc.,
Thebarton, South Australia) or using thioflavin S. The following antibodies were used for
immunohistochemical analysis: mAb66.1 (1:250), which recognizes residues 1-5 of
human A

38;

mAb2B4 to detect A42 (1:1000) and rabbit polyclonal antibody to detect

A40 (1:200; Biosource, Camarillo, CA) A42, respectively; rabbit polyclonal antibody to
collagen type IV to visualize cerebral microvessels (1:100; ThermoFisher, Rockford, IL);
and rabbit polyclonal antibodies to GFAP (1:200; Dako, Santa Clara, CA) and Iba-1
(1:200; Fujifilm Wako Pure Chemical, Osaka, Japan) for detection of astrocytes and
microglia, respectively. Prussian blue iron staining was performed to detect hemosiderin
deposits reflecting signs of previous microhemorrhage

39,40.

Von Kossa calcium staining

was used to detect small vessel occlusion/calcifications in the brain 41. In this case, tissue
sections were counterstained with pararosanline.

Quantitative Analysis of Vascular Pathologies The percent area amyloid coverage of
cerebral microvessels, percent area iron staining and the numbers of occluded/calcified

vessels in the frontotemporal cortex, thalamic, and hippocampal regions was determined
in rats at each of the specified ages using stereological principles as described

42.

Cerebral microvessel tortuosity in different brain regions was determined by
immunolabeling the vessels in brain tissue sections, measuring both the traced actual
vessel length and the direct straight line, end to end vessel length and dividing the actual
length/direct length.

Novel Exploration Behavioral Task A novel exploration paradigm was included to
measure perceptual slowing as represented in a slowed rate of stimulus encounters. This
was a common deficit observed in the similar Tg-SwDI mouse model

31.

Typically,

animals were placed in the open field apparatus to explore four novel and distinct objects
for a 5-min trial period. Interaction with an object was scored by the AnyMaze tm software
as entering into a predetermined zone surrounding the object.

Magnetic Resonance Imaging Analysis All rats were deeply anesthetized with
ketamine/xylazine (75 mg/kg / 10 mg/kg) i.p. followed by trans-cardial perfusion fixation.
First, vascular perfusion was conducted with 0.1% heparin/PBS (20cc/min for 5 min);
followed by 5% Magnevist in 10% buffered formalin solution (120 ml/rat at 20cc/min) using
a Pharmacia LKB P-1 peristaltic pump. Following perfusion fixation of the 12 months old
male rTg-DI and wild-type rats, the brains were removed from the skull with great care so
as to not damage the brain parenchyma. The brain specimens were immersed in PBS for
≥ 4 days. All MRI acquisitions were performed on a Bruker 9.4T/30 magnet (Bruker
BioSpin, Billerica MA) with BGA-12SHP imaging gradient system interfaced to an Avance
III console controlled by Paravision 5.1 software. For the post-mortem high resolution

scanning we used a cryogenically cooled RF coil as a transmit and receive. The brain
specimens were imbedded in fomblin (HT230-7K, Fluids & Greases, Kurt J. Lesker,
Jefferson Hills, PA) and underwent MRI using a 3D gradient echo sequence with the
following imaging parameters: TR/TE/FA=100ms/7~30ms/25° NEX=1 resolution=
0.08x0.08x0.08mm. The brain specimens were subsequently processed and stained for
hemosiderin deposits as described above. The stained whole brain slices were digitized
using an optical microscope (All-in-One Fluorescence Microscope BZ-X700), allowing the
entire brain slice to be used for matching with the corresponding high-resolution postmortem MRIs. The optical resolution achieved on the digitized brain slices was 0.377
µm/pixel.
The MRIs were displayed as isotropic 3D volumes using Amira software (Version
6.2). 3D MRIs acquired with a TE of 7ms and 18ms were used for the matching process.
The process to match the MRIs to the corresponding histological brain slice involved
several computational steps; and in all processing the histological brain slice served as
the master template or ‘reference’ and the 3D MRI was manipulated to match it. First, 35 histological slices of interest were chosen which included thalamic iron staining-positive
areas of micro-hemorrhages. Using the ‘slice’ feature in Amira, the MRI slice plane that
best matched the histological slice - (based on anatomical landmarks such as the shape
of the hippocampus, the corpus callosum, the fimbria and the shape of the ventral surface)
were defined. Using rigid matching (scaling in x- and y-directions) the MRI was matched
to the histological slice. Finally, the histological slice was overlaid onto the matched 2D
MRI to determine the MRI signatures associated with the iron stain-positive areas.

Statistical Analysis Histological and biochemical data were analyzed by t-test at the
0.05 significance level.

Behavioral testing data were analyzed by t-tests and the

performance of each subject for each testing day was the average latency of the two
trials.

Results

Low Level Expression of Human CAA Mutant APP in Brain Results in Progressive
and Extensive Microvascular CAA
To target production of human chimeric Dutch/Iowa CAA mutant in neurons of rat
brain we took a similar approach that was successfully used in the previous generation
of our Tg-SwDI mouse line 27. We used the neuronal-specific Thy1.2 expression cassette
to drive expression human APP harboring the familial AD Swedish K670N/M671L
mutations and the familial CAA Dutch E693Q and Iowa D694N mutations in neurons in
the rat brain. The Swedish APP mutations were included solely to enhance -secretase
processing and production of A peptides 43. The familial CAA Dutch and Iowa mutations
were included in the transgene to yield chimeric Dutch/Iowa CAA mutant A peptides in
brain which exhibit markedly enhanced fibrillogenic and vascular pathogenic properties
44,45.

The transgenic rats (rTg-DI) were generated by microinjection of the human

APP770-SwDI construct into oocytes in a pure Sprague-Dawley background. The
presence of the human APP transgene was confirmed in founder and subsequent

offspring rats by PCR analysis. All rTg-DI rats used in the subsequent characterization
experiments were heterozygous for the human APP transgene.
Two months old rTg-DI rats were evaluated for expression of the human APP
transgene

using

the

human

APP-specific

monoclonal

antibody

P2-1

34.

Immunohistochemical analysis presented in Figure 1A-F shows that human APP
expression was evident throughout the cortex, hippocampus and thalamus and was
restricted to neurons. Immunoblot analysis using mAbP2-1 confirmed that human APP
transgene expression was only observed in rTg-DI rats (Figure 1G). Subsequent
quantitative immunoblot analysis using the total (rat + human) APP-specific mAb22C11
showed that human transgene APP expression was modest and only about 50% higher
than the levels of endogenous rat APP seen in wild-type rats (Figure 1H).
The accumulation of human A peptides was measured in rTg-DI brains as they
aged over 12 months. A sandwich ELISA format was used that detected only human A
peptides 35,36. As the rTg-DI rats aged from 3-12 months there was a progressive increase
in the amounts of soluble A40 in brain whereas the amounts of soluble A42 remained
fairly constant over this time period (Figure 1I). The majority of soluble A peptides
(>90%) at each age were the shorter A40 isoform. On the other hand, there was a
progressive accumulation of both insoluble A40 and A42 as the rats aged (Figure 1J).
Again, the vast majority of accumulated insoluble A peptide was the shorter A40
isoform. These findings indicate that despite the low level of transgene human APP
expression there is an early-onset and progressive accumulation of Dutch/Iowa CAA
mutant A peptides in the brains of rTg-DI rats.

Early-Onset and Extensive Accumulation of Cerebral Microvascular Amyloid is
Associated with Behavioral Impairments and Exhibits a Characteristic Anti-Parallel
Alignment.
Since insoluble levels of cerebral A markedly increase with age in rTg-DI rats the
compartmental distribution of fibrillar amyloid was examined over time. Figure 2 shows
that as early as 3 months of age there was notable accumulation of cerebral
microvascular amyloid in the cortical, hippocampal and thalamic regions of the brain.
Further, as the rTg-DI rats aged to twelve months there was a dramatic increase in
cerebral microvascular amyloid deposition with nearly 45% and 70% of capillaries
covered in fibrillar amyloid in the thalamic and hippocampal regions, respectively (Figure
2J). Although the levels of capillary CAA were somewhat lower in the cortical areas still
nearly 30% of vessel surface was covered. Importantly, Figure 2K shows that these early
levels of capillary CAA in the rTg-DI rats were associated with the characteristic slowing
in the manner of exploration of unique objects arrayed in an open field (i.e. the novel
object exploration task) consistent with a form of perceptual slowing likely to result from
cortico-thalamic and hippocampal dysfunction and present in CAA 7.
Immunohistochemical analysis revealed that the vast majority of cerebral
microvascular amyloid was comprised of A40 (Figure 3A-C). Further, ELISA analysis of
isolated cerebral microvessels from rTg-DI rats confirmed that nearly 90% of the
accumulated amyloid was composed of A40 peptide (Figure 3D,E). Fibrillar
microvascular amyloid seeds were isolated from rTg-DI rats (Figure 3F) and FTIR
spectroscopy revealed a strong -sheet secondary structural component characteristic of

amyloid fibrils as indicated by the prominent spectral peak at ≈1632 cm -1 (Figure 3G).
Whereas wild-type A40 peptide slowly formed fibrils, the addition of the isolated
microvascular amyloid seeds promoted rapid fibril assembly of wild-type A40 as assayed
by thioflavin T fluorescence spectroscopy (Figure 3H). The rapid increase in fluorescence
argues that the A monomers are using the structural template provided by the seeds
as they associate with the growing fibrils. Recently, we found that fibrils seeded from
cerebral vascular amyloid exhibited intense FTIR bands characteristic of antiparallel strand structure 33. Notably, the newly formed seeded wild-type A40 fibrils from rTg-DI
microvascular amyloid exhibit a similar anti-parallel signature as reflected by the strong
FTIR spectral band at ≈1607 cm-1 (Figure 3I).

Accumulation of Cerebral Microvascular Amyloid in rTg-DI Rats Promotes Capillary
Structural Changes and Perivascular Inflammation
The prominent accumulation of cerebral microvascular amyloid in rTg-DI rats
caused pronounced structural changes to cerebral capillaries compared to similarly aged
wild-type rats. These capillary changes included the appearance of numerous “string
vessels”, which are remnants of capillaries with no endothelial cells

46,

and prominent

vessel fragmentation (Figure 4B). These structural changes were accompanied by a
significant (p < 0.001) increase in the tortuosity of the cerebral capillaries in the affected
brain regions further demonstrating the deleterious effects of vascular amyloid
accumulation (Figure 4C). Additionally, there was a significant (p < 0.001) increase in
capillary area in the thalamic region and an increased trend in the other brain regions
which may reflect the increased tortuosity (Figure 4D).

We also observed that cerebral microvascular amyloid in rTg-DI rats, which
engages

the

surrounding

brain

parenchyma,

is

associated

with

a

strong

neuroinflammatory response reflected by a robust increase of perivascular reactive
astrocytes (Figure 5B) when compared to similarly aged wild-type rats devoid of
microvascular amyloid (Figure 5A). Likewise, an elevated number of perivascular
activated microglia are present in rTg-DI rats in areas with microvascular CAA (Figure
5D). It was also noted that the lower number of microglia present in the similarly aged
wild-type rats were in the resting ramified surveillance mode with numerous extended
processes (Figure 5C) whereas the elevated numbers of microglia in rTg-DI rats exhibited
a bushy, activated morphology actively engaged with the fibrillar amyloid deposits on the
cerebral capillaries (Figure 5D). These findings indicate that the presence of prominent
cerebral microvascular amyloid in rTg-DI rats is accompanied by structural deterioration
of brain capillaries and a robust increase in activated perivascular glial cells.

Robust Microhemorrhages and Small Vessel Occlusions are Detected by MRI in
rTg-DI Rats
A prominent clinical feature of CAA in humans is the presence of cerebral
microbleeds

1,2.

The presence of microbleeds was histochemically evaluated by Perl’s

staining for perivascular hemosiderin deposits in groups of progressively aged rTg-DI
rats. Evidence of cerebral microbleeds was observed in the cortical and hippocampal
regions of 12 months old rTg-DI rats (Figures 6A and 6B, respectively). However,
microbleeds were particularly abundant in the thalamic region of the brain with various
presentations of perivascular iron deposits including tightly-associated crescent shaped

deposits (Figure 6C), complete circumferential involvement (Figure 6D), indications of
multiple bleeds in several adjacent microvessels (Figure 6E) and more diffuse
perivascular iron deposits (Figure 6F). Since it was often difficult to discriminate between
individual and grouped microbleeds we measured the area of iron deposition in the
different brain regions at 6 and 12 months. As shown in Figure 6G, signs of microbleeds
in the cortex were not observed at 6 months and were low at 12 months. However, in the
hippocampus small areas of microbleeds were detected at 6 months and this increased
as the rTg-rats aged to 12 months. Most notably, in the thalamus there was clear evidence
of microbleeds at 6 months which dramatically increased at 12 months of age with >1%
of the total thalamic area covered with perivascular iron deposits. Although microbleeds
are numerous in 12 months old rTg-DI rats large macrobleeds have not been observed
at this age.
Small vessel occlusions and calcifications are other microvasculopathies observed
in CAA patients

2,47,48.

Interestingly, in the thalamic region of prevalent microbleeds in

rTg-DI rats we noted numerous occluded microvessels (Figure 7A). Calcium staining of
adjacent brain tissue sections indicated calcifications in these small vessel occlusions
surrounded by areas of fibrinoid necrosis (Figure 7B). These microvascular occlusions
were bilateral and largely restricted to the ventral posterior lateral nucleus of the thalamic
region (Figure 7C). The overall numbers of these thalamic small vessel occlusions were
quantified in rTg-DI rats as they aged from 3 to 12 months of age. As shown in Figure 7D,
the occlusions were extremely rare or absent at 3 months of age. However, at 6 and 12
months the numbers markedly increased to ≈40 and ≈115 small vessel occlusions,

respectively in this thalamic region. At each age the majority of the vessel occlusions were
in capillaries but occasionally larger microvessels were also occluded.
We next performed studies in rTg-DI rats to characterize the microhemorrhages in
situ using in vitro MR microscopy. Figure 8 shows the results of MRI-to-histology matching
from a 12 months old rTg-DI rat with documented thalamic microhemorrhages and small
vessel occlusions. A 2D T2*-weighted MRI (TE=7ms) (Figure 8A) was matched to the
corresponding Perl iron-stained histological slice (Figure 8B). The dense dark areas in
the thalamus shown on the T2*-weighted MRI are corresponding to the microvessels
identified by Perl-stained iron deposits associated with the microbleeds and occluded
vessels. The Perl-stained histological slice is overlaid on the T2*-weighted images under
conditions where the histological slice has been rendered transparent to highlight the low
signal intensity ‘susceptibility’ features on the T2*-weighted MRI observed in the
thalamus, bilaterally, which is caused by presence of iron. Panels 8C and 8E are high
magnification of the inserts in panels 8B and 8D, respectively. Figures 8F and 8G are 3D volume rendered MRIs of the same rat showing the brain outlined in light yellow; and
the Perl-stain iron-positive associated low signal intensity area in the thalamus have been
volume rendered (green) to illustrate the near-perfect bilateral symmetry of the
microhemorrhages and occluded microvessels in the thalamic areas. Together, these
findings

indicate

that

rTg-DI

develop

numerous

and

consistent

thalamic

microhemorrhages and microvessel occlusions that are readily detected by T2*-weighted
MRI.

Discussion

CAA is a common cerebral small vessel disease of the elderly and a prominent
comorbidity of AD that promotes and exacerbates VCID, yet our understanding of the
condition remains limited and despite the high prevalence there is no effective treatment.
Several transgenic mouse models, that develop varying levels of CAA, have been in use
for more than a decade and have provided better insight into the pathogenesis of CAA 2332.

However, their usefulness to further investigate CAA from the point of view of faithfully

recapitulating the human condition is limited due to their biological evolutionary distance
from humans and the small size of their brains which can be problematic for effective
neuroimaging in vivo. Further, complicated cognitive testing to investigate VCID in the
setting of evolving CAA can be unreliable due to temperamental variability in mice

49.

Although naturally occurring models of CAA exist, most notably canines and non-human
primates, the experimental use of these species for large cohort experimentation and
testing is limited due to the cost and time needed for CAA to develop (decade or decades)
50.

Thus, there is a need for a better experimental model of CAA. The use of rats,

specifically transgenic rats, to investigate the pathogenesis of human CNS disorders
offers several distinct advantages over transgenic mice. First, rats are evolutionarily 4-5
million years closer to humans

51.

Thus, the genetics, physiology and brain morphology

of rats are better suited to model human CAA. Second, the larger brain size and increased
white-to-grey matter ratio of the rat enables structural neuroimaging studies with superior
contrast- and signal-to-noise ratio compared to mice. Lastly, rats provide the opportunity

for far more sophisticated cognitive testing compared to mice thereby bridging a gap in
knowledge as to how CAA drives VCID 52.
In the current study, we describe the generation and initial characterization of a
novel transgenic rat model (rTg-DI) of microvascular type 1 CAA. The rTg-DI rats were
designed from our earlier success in generating Tg-SwDI transgenic mice that develop
early-onset and progressive cerebral microvascular amyloid deposition

27.

In the rTg-DI

rats, we similarly expressed the human APP transgene harboring the Swedish familial
AD mutations and the -secretase cleavage site and the chimeric Dutch E693Q/Iowa
D694N familial CAA mutations in neurons in the brain. Indeed, low level neuronal
expression of the human APP transgene was observed in the rTg-DI rats (Figure 1).
This phenotype is important because it signifies that our new CAA model does not require
abnormal, vast over-expression of human APP and production of human A, that is
commonly found in other transgenic rodent models, which can introduce potential
confounds on neuronal function. This underscores that the robust cerebral accumulation
of A and specific development of microvascular CAA is a consequence of the chimeric
familial Dutch/Iowa mutations in the A peptide that is produced in the brains of these
rats. Interestingly, the early-onset development of microvascular CAA and associated
neuroinflammation coincides with early-onset and sustained cognitive deficits in rTg-DI
rats and offers the promise of a unique model for the future elucidation as to how CAA
can promote VCID.
The type and form of amyloid that accumulates in the cerebral microvasculature of
rTg-DI rats is remarkably similar to what is found in human CAA. For example, in contrast
to parenchymal amyloid plaques that largely accumulate fibrillar A42 in both humans

and rodent models, the fibrillar cerebral vascular amyloid deposits in rTg-DI rats are
composed primarily of the shorter A40 species

53,54.

In addition to the difference in the

length of the A peptide that forms the amyloid fibrils in either parenchymal plaques or
cerebral vascular deposits other micro-structural differences have been found. Recently,
we found that fibrils produced from seeds of cerebral vascular fibrillar amyloid deposits
exhibit increased intensity in FTIR spectra that is characteristic of anti-parallel structure
of the  strands forming the backbone of the A fibrils

33.

This structure is distinct from

the parallel registry observed in parenchymal plaque amyloid fibrils

55,56.

The -sheet,

anti-parallel fibril character is also observed in the cerebral microvascular amyloid
deposits of the rTg-DI rats (Figure 3). This important distinction between parenchymal
and cerebral vascular amyloid fibrils likely is involved in the pathogenesis of these two
types of deposits and may have important consequences with regards to subsequent
pathologies associated with each lesion type.
The accumulation of cerebral microvascular amyloid in rTg-DI rats promotes
distinct vessel and perivascular changes that are reflected in human CAA. Structurally,
the accumulation of microvascular amyloid causes significant alterations in capillary
morphology including increased vessel fragmentation, occlusion and tortuosity (Figure.
4). It has been suggested that these types of structural alterations can impair capillary
blood flow and may cause hypertension upstream from these sites of disruption

57.

On

the other hand, capillary tortuosity caused by microvascular amyloid can lead to poor
perfusion and downstream infarction

22,58.

Interestingly, there was an increase the

capillary area in the thalamic region of rTg-DI rats which might reflect the measured
increase in capillary tortuosity. Alternatively, it is possible that there is an increase in

vascularization in response to the extensive amyloid-mediated damage to the
microvasculature in this region. The changes in capillary morphology likely contribute to
increased perivascular disturbances in fluid homeostasis, inflammation, thrombosis and
microhemorrhage observed in CAA. In line with this, the accumulation of fibrillar amyloid
along the capillaries of rTg-DI rats induces a strong neuroinflammatory response
characterized by activation and robust increases in perivascular astrocytes and microglia
which is accompanied by consistent and frequent microbleeds and microvascular
occlusions, particularly in the thalamic region. These latter thrombotic events may result
directly from the excessive amyloid deposition in this region but are more likely to be
related to downstream inflammatory responses triggered by amyloid accumulation.
Currently, outside of biopsy or autopsy confirmation, the clinical diagnosis of CAA
is based on the “Boston criteria” which relies primarily on the detection of lobar
microbleeds based on MR imaging hypointensities resulting from perivascular
hemosiderin

3,59.

Similarly, MR imaging analysis of rTg-DI rats readily detected the

perivascular hemosiderin associated with the prevalent thalamic microbleeds. 3-D
reconstruction of the MR defined hypointensities illustrated the symmetrical and bilateral
nature of these consistent thalamic microbleeds (Figure 8). These findings suggest that
similar parameters for the “Boston criteria” diagnosis of CAA in humans can be applied
to rTg-DI rats allowing for the opportunity to investigate the longitudinal development and
persistence of these hallmark lesions by clinical relevant methodology.
Although the extent of CAA, capillary structural changes and perivascular
neuroinflammation is high in several brain regions of rTg-DI rats at six to twelve months
it is currently unclear why the most severe associated events of microhemorrhage and

vessel occlusion are largely restricted bilaterally to the thalamic regions. In human CAA,
cerebral microbleeds tend to be found in lobar cortical regions, in particular the occipital
cortex, and not so frequently in deeper brain structures. However, in cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL),
another type of cerebral small vessel disease, thalamic microbleeds are commonly
observed both in humans and in the equivalent transgenic mouse model

60-62.

Perhaps

the thalamic region in rats exhibits differential blood flow or perivascular clearance
mechanisms compared to humans and in other regions of the rat brain making this region
particularly susceptible to excessive perivascular amyloid deposition. Alternatively, rat
capillaries/microvessels in the thalamic areas may possess a different vascular
environment compared to other brain regions. Future studies are needed to evaluate
these possibilities. Although the anatomical distribution of CAA and cerebral vascular
thrombotic lesions may be somewhat different between rTg-DI rats and humans this
unique model provides new opportunities to investigate the pathogenic development of
CAA and its relation of VCID. Further, rTg-DI rats provide an improved platform for the
development of biomarkers and preclinical testing of therapeutic interventions for this
common small vessel disease.
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Figure Legends
Figure 1. Analysis of transgenic human APP expression and progressive A
accumulation in rTg-DI rats.
Brain sections from two months old rTg-DI rats were immunolabeled with the mouse
monoclonal antibody mAbP2-1 to specifically detect human APP (green) and the rabbit
polyclonal antibody NeuN to detect neurons (red). There was widespread human APP
expression in neurons in the cortex (A,B), hippocampus (B,D) and thalamus (E,F). Scale
bars = 10 µm (A,C,E) and 50 µm (B,D,F). (G) Immunoblot analysis of human APP
expression in total brain homogenates from wild-type rats and rTg-DI rats. (H)
Quantitative immunoblotting was performed to measure total APP (endogenous rat
APP + transgenic human APP) in brain homogenates of wild-type rats and rTg-DI rats.
The data presented are the means ± S.D. of 5 rats per each group (*p < 0.05). The level
of transgene human APP expression is ≈50% the amount of endogenous rat APP. The
levels of soluble (I) and insoluble (J) A40 and A42 peptides in the forebrain of
progressively aged rats were measured by ELISA as described under “Experimental
Procedures.” The data presented are the means ± S.D. of triplicate measurements in 5-6
rTg-DI rats per group.

Figure 2. Progressive Accumulation of Microvascular CAA in rTg-DI Rats.
Brain sections from rTg-DI rats at three months old (A-C), six months old (D-F) and twelve
months old (G-I) were stained for fibrillar amyloid using thioflavin-S (green) and
immunolabeled for collagen type IV to identify cerebral microvessels (red). Scale bars =

50 µM. The rTg-DI rats develop early-onset and progressive cerebral microvascular
fibrillar amyloid in the cortical, hippocampal and thalamic regions. (J) Quantitation of
microvascular thioflavin-S positive amyloid load in different brain regions of three months
(blue bars), six months (gray bars) and twelve months (red bars) old rTg-DI rats. Data
shown are mean ± S.D of 6-7 rTg-DI rats per group. (K) rTg-DI rats showed consistently
fewer return approaches within a session to four novel objects placed in an open field
arena compared to WT rats at 3 and 12 months of age (*p < 0.05).

Figure 3. Analysis of Cerebral Microvascular A Deposition in rTg-DI Rats.
Brain sections from rTg-DI rats at twelve months of age were immunolabeled with an
antibody specific for A40 (red) (A) and an antibody specific for A42 (green) (B) and
merged (C). Scale bar = 50 µm. (D) Cerebral microvessels were isolated from twelve
months old rTg-DI rats and stained with thioflavin-S to visualize fibrillar amyloid deposits
(green) and immunolabeled with an antibody to collagen IV to view the cerebral
microvessels (red). Scale bar = 50 µm. (E) ELISA measurements were performed to
determine the amounts of A40 and A42 in the microvessels isolated from rTg-DI rat
brain. Data shown are mean ± S.D. of 5 rTg-DI rats. (F) Cerebral microvascular amyloid
deposits after digestion and removal of the capillaries and stained for fibrillar amyloid
using thioflavin S (green). Scale bar = 50 µm. (G) FTIR spectra in the region of the amide
I vibration of vascular amyloid isolated from vessels of rTg-DI rat brain. (H) Thioflavin T
fluorescence of fibril formation from seeds obtained from isolated vascular amyloid.
Thioflavin fluorescence increases rapidly upon the addition of 100 M A40-WT monomer
to sonicated vascular amyloid (black). Monomeric A40-WT peptide exhibits a much

slower increase in fluorescence in the absence of fibril seeds (blue). (I) FTIR spectra in
the region of the amide I vibration of A40-WT fibrils produced from seeds of the rat
vascular amyloid. The amide I vibration at 1632 cm -1 corresponds to -sheet. The
vibration at 1607 cm-1 corresponds to the amide vibration shifted as a result of

13C=O

labels at the backbone carbonyls of Leu17, Ala21, Gly33 and Gly37. The large intensity
of the 1607 cm-1 band relative to the -sheet vibration at 1632 cm-1 is characteristic of
anti-parallel -sheet structure. The spectra were obtained after incubation for 48 h at 37
°C.

Figure 4. Cerebral Microvascular Structural Changes in rTg-DI Rats.
Brain sections from wild-type rats (A) and rTg-DI rats (B) at twelve months of age were
immunolabeled with an antibody to collagen IV to identify cerebral microvessels. Images
shown are from the thalamic region of the rats. Numerous fragmented and string vessels
(white arrows) were identified in the rTg-DI rats. Scale bars = 50 µm. (C) The tortuosity
of the cerebral capillaries was measured in the cortex, hippocampus and thalamic region
of wild-type and rTg-DI. Data shown are mean ± S.D. of 5-6 rats per group (***p < 0.001).
(D) The capillary area was measured in the cortex, hippocampus and thalamic region of
wild-type and rTg-DI. Data shown are mean ± S.D. of 5-6 rats per group (***p < 0.001).
The data show that cerebral capillaries in rTg-DI rats exhibit structural abnormalities,
increased tortuosity and, in the thalamic region, increased vascularization.

Figure 5. Perivascular Glial Activation in rTg-DI Rats.

Twelve months old brain sections from wild-type rats (A,C) and rTg-DI rats (B,D) were
stained for fibrillar amyloid (blue), immunolabeled with an antibody to collagen IV to
identify cerebral microvessels (red) and immunolabeled with an antibody to GFAP to
identify astrocytes (green) (A,B) or immunolabeled with an antibody to Iba-1 to identify
microglia (green) (C,D). Scale bars = 50 µm. rTg-DI rats exhibit strong increases in
perivascular reactive astrocytes and activated microglia in response to the prominent
cerebral microvascular amyloid.

Figure 6. Prominent Cerebral Microhemorrhages in rTg-DI Rats.
Twelve months old brain sections from rTg-DI rats were stained for hemosiderin to identify
microhemorrhages (blue) in the cortex (A), hippocampus (B) and the thalamus (C-F).
Scale bars = 50 µm. The percent area fraction of hemosiderin staining was quantitated in
the cortex, hippocampus and thalamus of six months old (gray) and twelve months old
(red) rTg-DI rats (G). Data represent the mean ± S.D. of 6-7 rTg-DI rats per group.
Progressive and consistent accumulation of microbleeds was observed, particularly in the
thalamus, of rTg-DI rats.

Figure 7. Progressive Cerebral Microvascular Occlusions in rTg-Rats.
Twelve months old brain sections from rTg-DI rats were stained for hemosiderin to identify
microhemorrhages (blue) and counterstained with pararosanline (pink) in the thalamus
(A). Scale bar = 50 µm. Adjacent tissue sections were stained for calcium (black) and
counterstained with pararosanline (pink) in the thalmus (B). Scale bar = 50 µm. Lower
magnification revealed that the occluded, calcified microvessels were restricted to the

thalamic region (C). Scale bar = 200 µm. The number of thalamic microvessel occlusions
were counted in progressively aged rTg-DI rats (D). Data represent the mean ± S.D. of 56 rTg-DI rats per group. Numerous occluded capillary/microvessels were observed
around microbleeds specifically in the thalamic region of rTg-DI rats.

Figure 8. Detection of Microhemorrhage by MRI in rTg-DI Rats. (A) 2D T2*-weighted
MRI (TE=7ms) matched to the corresponding Perl-stained histological slice (B). The
dense dark areas in the thalamus shown on the T2*-weighted MRI (A) correspond to
microvessels characterized by Perl stain-positive microbleeds and occluded vessels. (D)
Perl-stained histological slice was overlaid on the T2*-weighted images under conditions
where the histological slice have been rendered transparent to highlight the low signal
intensity ‘susceptibility’ features on the T2*-weighted MRI observed bilaterally in the
thalamus, which is caused by presence of hemosiderin. Scale bars = 500 µm. Panels (C)
and (E) are higher magnification of the inserts in (B) and (D), respectively. Scale bars =
100 µm. Panels (F) and (G) are 3D volume rendered MRIs of the same rat showing the
brain outlined in light yellow; and the Perl stain-positive associated low signal intensity
area in the thalamus have been volume rendered (green) to illustrate the near-perfect
symmetry of the microhemorrhage/occluded microvessels areas. Scale bar = 3.5 mm.
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